Skip to main content
Premium Trial:

Request an Annual Quote

Israeli Protein Separation Startup Obtains $14 Million in Financing

NEW YORK, March 5 – Proteologics, a proteomics startup in Rehovot, Israel, has obtained $14 million in financing from venture capital firms, the company said Monday.

Concord Ventures, also based in Israel, led the financing with $9 million, with U.S .Venture Capital firm ABS Ventures and the Giza Fund, one of Israel's largest venture capital groups, supplying the remainder.

Proteologics is hoping to commercialize a technology for separating proteins—specifically membrane and high molecular weight hydrophobic proteins—based on the research of two physicists working in Novosibirsk, Russia, said Pennina Langer Safer, a principal with Concord Ventures.

“To the best of my knowledge, they are the only ones with the technology for this kind of protein separation,” said Safer.

Membrane proteins are important as drug targets because they regulate access to the interior of the cell. With most existing technologies, these proteins are difficult to isolate, added Safer.

Proteologics' separation technique is compatible with existing 2-D gel separation technology, including mass spectrometry systems, said Safer.

The company currently has about 25 employees, and has plans to develop its own proprietary drug discovery program, in addition to finding strategic partners, Safer said.

“What excited us is that they’ve taken some physics and chemistry-based technology and applied it to solving biological problems,” Safer said.

Proteologics was not immediately available for comment.  

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.